Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-04-03
1998-07-14
MacMillan, Keith
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514654, A61K 31445, A61K 31135
Patent
active
057804850
ABSTRACT:
A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
REFERENCES:
patent: 4975440 (1990-12-01), Flockerzi et al.
patent: 4994461 (1991-02-01), Ulrich
patent: 5403847 (1995-04-01), Gluchowski et al.
patent: 5508306 (1996-04-01), Chiu et al.
Forray, C., et al. "The .alpha..sub.1C -Adrenergic Receptor that Mediates Smooth Muscle Contraction in Human Prostate Has the Pharmacological Properties of the Cloned Human .alpha..sub.1c Subtype," Molecular Pharmacology, 45, 703-708 (1994); U.S.A. (Exhibit 3).
Forray, C., Chiu, G., et al. Effects of Novel Alpha-1C Adrenergic Receptor Antagonists on the Contraction of Human Prostate Smooth Muscle, American Urological Association Eighty-Ninth Annual Meeting, May 14-19, 1994, The Journal of Urology, 151(5), Abstract #159 (May 1994); U.S.A. (Exhibit 4).
Forray, C., Bard, J.A., et al. "Comparison of the Pharmacological Properties of the Cloned Bovine, Human, and Rat .alpha..sub.1C -Adrenergic Receptors," The FASEB Journal, 8(4), Abstract #2042 (1994) U.S.A. (Exhibit 5).
Gong, G., et al. .alpha..sub.1C -Adrenergic Antagonists and Orthostatic Hypotension in the Rat, The FASEB Journal, 8(4), Abstract #2043 (1994); U.S.A. (Exhibit 6).
Lepor, H., et al. "Localization of Alpha.sub.1c Adrenoceptor (.alpha..sub.1C AR) Subtypes in the Human Prostate," American Urological Association Eighty-Ninth Annual Meeting, May 14-19, 1994, The Journal of Urology, 151(5), Abstract #614 (May 1994); U.S.A. (Exhibit 7).
Perez, J.-L., et al. "Is the .alpha..sub.1C -Adrenergic Receptor the .alpha..sub.1A -Subtype?" The FASEB Journal, 8(4), Abstract #2041 (1994); U.S.A. (Exhibit 8).
Tang, R., et al. "Localization of Alpha 1C Adrenoceptor (.alpha..sub.1C AR) Subtypes in the Human Prostatic Tissue," The FASEB Journal, 8 (5), Abstract #5070 (1994); U.S.A. (Exhibit 9).
Wetzel, J.M., et al. "Structural and Functional Studies of the Human .alpha..sub.1C Adrenergic Receptor: The Orientation of Transmembrane Helix 5," The FASEB Journal, 8(4), Abstract #2182 (1994); U.S.A. (Exhibit 10).
Archibald, J.L. et al., "Antihypertensive Ureidopiperidines," Journal of Medicinal Chemistry (1980), vol. 23, pp. 857-861.
Boer, R. et al., "(+)-Niguldipine binds with very high affinity to Ca.sup.2+ channels and to a subtype of .alpha..sub.1 -adrenoreceptors," European Journal of Pharmacology--Molecular Pharmacology Section (1989), vol. 172, pp. 131-145.
Gup, D.I. et al., "Autonomic Receptors in Human Prostate Adenomas," Journal of Urology (1990), vol. 143, pp. 179-185.
Hieble, J.P. et al., "In vitro characterization of the .alpha..sub.1 -adrenoreceptors in human prostate," European Journal of Pharmacology (1985), vol. 107, pp. 111-117.
Lepor, H. and Baumann, M. et al., Medline Abstracts (1988), Abst. No. 88317114, "The Alpha Adrenergic Binding Properties of Terazosin in the Human Prostate Adenoma and Canine Brain," Journal of Urology (1988), vol. 140(3), pp. 668-671.
Lepor, H. and Knapp-Maloney, G. et al., "A Dose Titration Study Evaluating Terazosin, A Selective, Once-A-Day .alpha.1-Blocker for the Treatment of Symptomatic Benign Prostatic Hyperplasia," Journal of Urology (1990), vol. 144, pp. 1393-1398.
Lepor, H. and Shapiro, E. et al., Medline Abstracts (1988), Abst. No. 88317113, "The Effect of Electrocautery on Neurotransmitter Receptor Binding Assays in the Canine Prostate," Journal of Urology (1988), vol. 140(3), pp. 664-667.
Lomasney, J.W. et al., "Molecular Cloning and Expression of the cDNA for the .alpha..sub.1A -Adrenergic Receptor," Journal of Biological Chemistry (1991), vol. 266, pp. 6365-6369.
Marshall, I. et al., "Human Alpha.sub.1C -Adrenoceptor: Functional Characterization In Prostate," Meeting of the British Pharmacological Society (1992), Abst. No. C97.
Ramarao, C.S. et al., "Genomic Organization and Expression of the Human .alpha..sub.1B -Adrenergic Receptor," Journal of Biological Chemistry (1992), vol. 267, pp. 21936-21944.
Yamada, S. et al., ".alpha..sub.1A -Adrenergic Receptors in Human Prostate: Characterization and Alteration in Benign Prostatic Hypertrophy," Journal of Pharmacology and Experimental Therapeutics (1987), vol. 242, pp. 326-330.
Chemical Abstracts and 1988:563185, Kaminka et al, 1988.
Chemical Abstracts and 1987:513718, Yamada et al, 1987.
Branchek Theresa A.
Chiu George
Forray Carlos C.
Gluchowski Charles
Hartig Paul R.
MacMillan Keith
Synaptic Pharmaceutical Corporation
White John P.
LandOfFree
Use of .alpha..sub.1c specific compounds to treat benign prostat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of .alpha..sub.1c specific compounds to treat benign prostat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of .alpha..sub.1c specific compounds to treat benign prostat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1882111